Table 1 ROC for baseline IGF-IR-related serum analytes in patients receiving PCF20

From: Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab

 

PFS at 3 months

PFS at 6 months

Analyte

ROC AUC 95% CI

P -value

ROC AUC 95% CI

P -value

Total IGF-1

0.368–0.758

0.566

0.476–0.846

0.140

fIGF-1

0.536–0.852

0.026

0.661–0.933

0.007

IGF-2

0.430–0.811

0.290

0.460–0.834

0.215

Insulin

0.387–0.769

0.457

0.464–0.832

0.213

IGFBP-1

0.531–0.880

0.040

0.405–0.784

0.401

IGFBP-2

0.498–0.862

0.086

0.361–0.752

0.650

IGFBP-3

0.306–0.652

0.842

0.478–0.809

0.178

  1. Abbreviations: AUC=area under the ROC curve; CI=confidence interval; IGF=insulin-like growth factor; fIGF-1=free insulin-like growth factor 1; IGFBP=insulin-like growth factor binding protein; IGF-IR=insulin-like growth factor type 1 receptor; PCF=paclitaxel and carboplatin in combination with figitumumab; PFS=progression-free survival; ROC=receiver operating characteristics.
Back to article page